Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | AGXT | P21549 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15474497 | 0.85 | NOX1 (0.44) | MAOBCNR2SMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL15475095 | 0.83 | APP (0.40) | APPMAOBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8128063 | 0.79 | ALDH1A1 (0.42) | NPC1RAB9APOLBSMN1; SMN2TDP1 | |
| SCHEMBL10748336 | 0.78 | ALDH1A1 (0.38) | MAOBPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL11644369 | 0.77 | ALDH1A1 (0.35) | TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL3211262 | 0.77 | BACE1 (0.36) | NPC1RAB9ASMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL15474804 | 0.75 | CYP3A4 (0.42) | — | |
| SCHEMBL10893246 | 0.74 | MAPK1 (0.40) | CNR1CNR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15474902 | 0.73 | ALDH1A1 (0.38) | TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL2451926 | 0.72 | APP (0.49) | APPMAOBIDO1AGXTCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3323816-A1 | NOVEL PYRAZOLE DERIVATIVE | Green Tech Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
| US-9399635-B2 | Pyrazole derivative | GREEN TECH CO., LTD. (JP) | 2016-07-26 | — | — | US | disclosed |
| US-20140088029-A1 | NOVEL PYRAZOLE DERIVATIVE | PHARMA EIGHT CO., LTD. (JP) | 2014-03-27 | — | — | US | disclosed |
| EP-2698368-A1 | NOVEL PYRAZOLE DERIVATIVE | Pharma Eight Co. Ltd (JP) | 2014-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088029-A1 | NOVEL PYRAZOLE DERIVATIVE | PSEN2, MAPT, PSEN1 | APP 4/4885MAOB 1430/4885IDO1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.